Myovant – Sumitovant

July 27, 2022Myovant Sciences Announces Corporate Updates and Financial Results for First Fiscal Quarter 2022
July 13, 2022The Impact of Urinary Incontinence Related to Overactive Bladder on Long-Term Care Residents and Facilities in the U.S. Highlighted in New Survey
July 07, 2022Urovant Sciences® Named One of 2022 “Best Places to Work” in Orange County
July 05, 2022Urovant Sciences and Pierre Fabre Médicament Enter into Exclusive License Agreement to Commercialize Vibegron for the Treatment of Overactive Bladder in the European Economic Area, UK, and Switzerland
June 17, 2022Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 2 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women with Endometriosis-Associated Pain
June 02, 2022Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE®
May 17, 2022Spirovant Launches State-of-the-Art Laboratory and Headquarters
May 15, 2022Urovant Sciences® Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association Meeting
May 13, 2022Urovant Sciences® Presents Interim Data from Phase 2a Study of Investigational Novel Gene Therapy, URO-902, Supporting Safety, Tolerability, and Efficacy Endpoints at 2022 American Urological Association Meeting
May 10, 2022Myovant Sciences Announces Corporate Updates and Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2022
1 2 3 … 22 Next »